Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

134
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
134
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

150
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
150
Actuarial Approach01:20

Actuarial Approach

79
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
79
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

243
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
243
Survival Curves01:18

Survival Curves

164
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
164

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing anxiety in high-altitude Tibetan communities: validation of a Tibetan version GAD-7.

Frontiers in psychology·2026
Same author

Clinodiside A, an active metabolite in Clinopodii herba, alleviates dextran-sulfate-sodium-induced ulcerative colitis.

Frontiers in pharmacology·2026
Same author

Experimental and numerical investigation of stress spatiotemporal response of fault plane during underground coal seam advancement.

Scientific reports·2026
Same author

Online axial drift measurement of ball screw ends using dual-wavelength microwave photonics.

Applied optics·2026
Same author

Associations of Anxiety and Depression and Hypomanic Traits with Self-Informant Discrepancies in Adults First Diagnosed with ADHD in Adulthood: A Cross-Sectional Study.

Journal of clinical medicine·2026
Same author

High-Temperature Mechanical Characterization of CeO<sub>2</sub> as a Ceramic Surrogate Fuel Based on FIB and Nanoindentation.

Materials (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jul 8, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

Sample size calculation for multi-arm parallel design with restricted mean survival time.

Yaxian Chen1, Kwok Fai Lam1,2, Jiajun Xu3

  • 1Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong.

Statistical Methods in Medical Research
|December 14, 2023
PubMed
Summary

This study introduces a new method for designing multi-arm clinical trials using restricted mean survival time (RMST). The approach simplifies sample size calculations for comparing multiple cancer treatments, enhancing trial efficiency.

Keywords:
Multi-arm designRMSTdose-findingglobal testmultiple testingsample size

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

292
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Related Experiment Videos

Last Updated: Jul 8, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

292
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Oncology Research

Background:

  • Restricted Mean Survival Time (RMST) is gaining prominence over hazard ratios for time-to-event outcomes in oncology clinical trials.
  • Current methods for RMST comparison face challenges in multi-arm trials (three or more groups), particularly regarding simultaneous intervention comparison, multiple testing, and sample size determination.

Purpose of the Study:

  • To propose a novel method for designing multi-arm clinical trials with right-censored survival endpoints based on RMST.
  • To provide a framework for both phase II/III settings, incorporating a global test and a modeling-based multiple comparison procedure.
  • To address the obstacle of sample size determination in multi-arm RMST comparisons.

Main Methods:

  • Developed a novel framework for multi-arm clinical trial design using RMST.
  • Introduced a closed-form sample size formula based on a multi-arm global test.
  • Incorporated a sample size determination procedure for multiple comparisons in phase II dose-finding studies.
  • Accounted for non-proportional hazards and staggered patient entry in sample size assessment.

Main Results:

  • The proposed method offers a robust and flexible approach to multi-arm trial design.
  • Achieved smaller sample sizes while maintaining target power compared to conventional methods.
  • Demonstrated validity and accuracy through simulation studies and real clinical trial examples.

Conclusions:

  • The novel RMST-based framework facilitates efficient and accurate design of multi-arm clinical trials in oncology.
  • The method addresses key challenges in sample size determination and multiple testing for complex trial designs.
  • This approach enhances the practical application of RMST in advancing cancer treatment research.